Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame?

Kılıçarslan, Necati AlpBörekçi, ŞerminÖzdemir, Gül NihalSayitoğlu, MügeEskazan, Ahmet Emre2022-10-112022-10-112022Kılıçaslan NA, Börekçi Ş, Özdemir GN, Sayitoğlu M, Eşkazan AE. Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame? Expert Rev Respir Med. 2022 Sep 15:1-4. doi: 10.1080/17476348.2022.2122445. Epub ahead of print. PMID: 36069271.1747-6348http://doi.org/10.1080/17476348.2022.2122445https://hdl.handle.net/20.500.12713/3182No Abstract Availableeninfo:eu-repo/semantics/closedAccessChronic Myeloid LeukemiaDasatinibLymphocytosisPleural EffusionTyrosine Kinase Inhibitor.Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame?Editorial1436069271WOS:0008547734000012-s2.0-85138278976Q210.1080/17476348.2022.2122445Q1